Mar 11, 2021 — 4 min read
Lunit SCOPE IO, an AI therapeutic biomarker platform, can analyze immune phenotype of NSCLC patients at a higher accuracy level compared to pathologists
With pathological consensus, AI-based analysis can be utilized as a novel biomarker of immunotherapy in the digital pathology era
Findings to be presented at USCAP online poster presentation, Monday, March 15
Lunit today announced an upcoming abstract presentation featuring its AI-based predictive analysis of immune phenotype at the 2021 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, to be held online on March 13-18.
Lunit, a leading medical AI startup, focuses on developing AI biomarkers that accurately predict cancer patients’ response to immunotherapy, based on digital analysis of histopathological whole slide images. With its proprietary deep learning algorithm, Lunit is developing an AI therapeutic biomarker platform called ‘Lunit SCOPE IO’.
In the abstract, Lunit presents the performance of Lunit SCOPE IO in the analysis of whole-slide images of non-small cell lung cancer (NSCLC) patients. The abstract, titled, ‘Development and validation of deep learning-based pathologic classification of immune phenotype in non-small cell lung cancer,’ will be presented during the poster session on Monday, March 15, 2:15 p.m. Pacific Time.
According to recent studies, Lunit SCOPE IO showed remarkable performance in classifying the immune phenotypes of NSCLC patients, by analyzing their H&E whole slide images. In the upcoming USCAP abstract presentation, the researchers share the findings from further validation of the AI’s performance, by directly comparing the AI detection results with that of pathologists’ diagnostic results.
By analyzing H&E whole slide images of NSCLC patients, the AI software accurately predicted three immune phenotypes (3-IP) by 92.4%. This showed a higher rate compared to the 3-IP annotation made by independent pathologists with the same validation set, which showed an 80.5% average concordance rate.
“Development of consensus and utilizing AI-based analysis to classify immune phenotypes are of high interest due to the lack of pathologic consensus for the classification of tumor infiltrating lymphocyte(TIL) distribution, which is the key factor in prediction of response to immunotherapy,” said Dr. Chan-Young Ock, Chief Medical Officer of Oncology at Lunit, who led the study. “As each immune phenotype leads to different survival rates and response to immune checkpoint inhibitors, it was important to validate that our AI algorithm can accurately predict such classification.”
“Although more and more cancer patients are treated with immune checkpoint inhibitors, prediction of response to them is limited. Novel biomarkers are needed to identify more patients that respond well to this powerful treatment,” said Brandon Suh, CEO of Lunit. “The value that this study presents is in the accuracy of AI-based pathologic classification of immune phenotype, demonstrating the possibility of Lunit SCOPE IO to be utilized as a novel biomarker of immunotherapy in the digital pathology era.”
Based on the company’s commitment in clinical research and studies, Lunit’s findings have also been presented in ASCO and AACR since 2019, acknowledged for its potential value. “We will continue our development as we plan to expand the scope of our analysis and further train the algorithm into a reliable product that can help improve patient outcome,” added Suh.
Abstract #: 780
Abstract Title: Development and Validation of Deep Learning-Based Pathologic Classification of Immune Phenotype in Non-Small Cell Lung Cancer
Presentation Details: Poster Session on Monday, March 15, 2021 from 2:15 PM - 3:15 PM Pacific Time
USCAP website: https://www.uscap.org/uscap-annual-meeting/
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Uncertainty and Deep Learning
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
ANNOUNCING: BRANDON SUH, OUR NEW CEO
Lunit preps Korean IPO led by NH Investment Bank
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Named to the 2019 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
Lunit Secures $26M in Series C Funding Round, Led by Asian Investors
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit Awarded as Technology Pioneer by World Economic Forum
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Lunit Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
What do medical studies say about AI for COVID-19 management?
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI